SHANDONG SITO BIO-TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.26 CNY | -1.25% |
|
-8.53% | -27.91% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,532 | 2,647 | 3,752 | 2,705 | - | - |
| Enterprise Value (EV) 1 | 2,532 | 2,647 | 3,752 | 2,705 | 2,705 | 2,705 |
| P/E ratio | -14 x | 72.6 x | 79.1 x | 47.5 x | 36.6 x | 32.4 x |
| Yield | - | - | - | 0.07% | 0.14% | 0.14% |
| Capitalization / Revenue | - | - | - | 1.93 x | 1.76 x | 1.62 x |
| EV / Revenue | - | - | - | 1.93 x | 1.76 x | 1.62 x |
| EV / EBITDA | - | - | - | 9.95 x | 8.59 x | 7.82 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | 1.36 x | 1.32 x | 1.27 x |
| Nbr of stocks (in thousands) | 171,928 | 171,604 | 189,702 | 189,702 | - | - |
| Reference price 2 | 14.72 | 15.42 | 19.78 | 14.26 | 14.26 | 14.26 |
| Announcement Date | 21-04-19 | 22-04-25 | 24-04-28 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 1,404 | 1,538 | 1,669 |
| EBITDA 1 | - | - | - | 272 | 315 | 346 |
| EBIT 1 | - | - | - | 67 | 85 | 98 |
| Operating Margin | - | - | - | 4.77% | 5.53% | 5.87% |
| Earnings before Tax (EBT) 1 | - | - | - | 66 | 84 | 97 |
| Net income 1 | -179.8 | 36.21 | 45.6 | 57 | 73 | 84 |
| Net margin | - | - | - | 4.06% | 4.75% | 5.03% |
| EPS 2 | -1.050 | 0.2125 | 0.2500 | 0.3000 | 0.3900 | 0.4400 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | 0.0100 | 0.0200 | 0.0200 |
| Announcement Date | 21-04-19 | 22-04-25 | 24-04-28 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | 2.89% | 3.56% | 3.94% |
| ROA (Net income/ Total Assets) | - | - | - | 1.7% | 2.11% | 2.34% |
| Assets 1 | - | - | - | 3,353 | 3,460 | 3,590 |
| Book Value Per Share 2 | - | - | - | 10.50 | 10.80 | 11.30 |
| Cash Flow per Share 2 | - | - | - | 3.400 | 1.430 | 1.590 |
| Capex 1 | - | - | - | 171 | 182 | 213 |
| Capex / Sales | - | - | - | 12.18% | 11.83% | 12.76% |
| Announcement Date | 21-04-19 | 22-04-25 | 24-04-28 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.26
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.91% | 375M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 300583 Stock
- Financials Shandong Sito Bio-technology Co., Ltd.
